Diagnostic and prognostic significance of SLC50A1 expression in patients with primary early breast cancer

Qunchen Zhang; Yutong Fang; Chuanghong She; Rongji Zheng; Chaoqun Hong; Chunfa Chen; Jundong Wu

doi:10.3892/etm.2022.11553

Diagnostic and prognostic significance of SLC50A1 expression in patients with primary early breast cancer

Exp Ther Med. 2022 Aug 5;24(4):616. doi: 10.3892/etm.2022.11553. eCollection 2022 Oct.

Authors

Qunchen Zhang^{1

2}, Yutong Fang^{1

2}, Chuanghong She^{1

2}, Rongji Zheng^{1

2}, Chaoqun Hong^{2

3}, Chunfa Chen¹, Jundong Wu^{1

2

3}

Affiliations

¹ The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515041, P.R. China.
² Department of Central Laboratory, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515041, P.R. China.
³ Guangdong Provincial Key Laboratory for Breast Cancer Diagnosis and Treatment, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515041, P.R. China.

Abstract

There is a lack of validated biomarkers for the diagnosis of early breast cancer (EBC). The current study aimed to determine the diagnostic and prognostic value of solute carrier family 50 member 1 (SLC50A1) in patients with EBC. Therefore, 123 patients with EBC, 30 patients with benign breast disease (BBD) and 26 healthy controls (HCs) were recruited. The serum levels of SLC50A1 in paired sera of 40 postoperative patients were assessed by ELISA. Immunohistochemical staining for SLC50A1 was performed in surgical tissue derived from 83 patients with EBC and 30 patients with BBD. mRNA expression of SLC50A1 and its diagnostic and prognostic value in patients with EBC was evaluated using an RNA-sequencing database. The results showed that serum levels of SLC50A1 in patients with EBC were significantly higher compared with those in patients with BBD and HCs (both P<0.001). Additionally, receiver operating characteristic curve analysis revealed that the serum levels of SLC50A1 distinguished patients with EBC from patients with BBD and HCs with a sensitivity of 76.42% and specificity of 76.79% [area under the curve (AUC)=0.783; P<0.001]. The diagnostic value of SLC50A1 was significantly greater than that of carcinoembryonic (P<0.005) and carbohydrate antigen 15-3 (P<0.029). Furthermore, the number of SLC50A1 positive cells significantly increased in tissue of patients with EBC compared with patients with BBD (P<0.001). A positive association between serum levels of SLC50A1 and its expression in tissue samples was observed in patients with EBC (ρ=0.700; P<0.001). Additionally, bioinformatics analysis verified the diagnostic value of SLC50A1, with an AUC of 0.983 (P<0.001). Multivariate analysis demonstrated that SLC50A1 was an independent prognostic factor in patients with EBC with a hazard ratio of 1.917 (P=0.013). These findings indicated that SLC50A1 may be a potential diagnostic biomarker for primary EBC and that SLC50A1 upregulation may be associated with unfavorable prognosis in patients with EBC.

Keywords: SLC50A1; biomarker; diagnostic; early breast cancer; prognosis.

Grants and funding

Funding: The present work was supported by Science and Technology Project of Shantou, China [grant no. 170828211930352; (2018)120] and Clinical Research Fund Project of Wu Jieping Medical Foundation (grant no. 320.6750.2021-10-34).